ANI Pharmaceuticals stock price target raised to $93 from $84 at H.C. Wainwright

ANI Pharmaceuticals (ANIP) reported robust second-quarter 2025 results, with adjusted EPS of $1.80 and revenue of $211.4 million, significantly exceeding consensus estimates, primarily driven by strong Cortrophin Gel sales. This strong performance prompted H.C. Wainwright to raise its price target to $93.00 and led ANI to increase its full-year 2025 guidance for revenue, adjusted EBITDA, and EPS. While the company demonstrates solid commercial execution and healthy liquidity, InvestingPro analysis indicates the stock is currently trading above its fair value.

Analysis

ANI Pharmaceuticals (ANIP) delivered a robust second quarter for 2025, significantly outperforming market expectations and prompting an upward revision in analyst sentiment. The company reported adjusted EPS of $1.80, a substantial beat over the $1.41 FactSet consensus, on revenue of $211.4 million, which surpassed the forecast of $187.34 million. This performance was primarily driven by the exceptional growth of its key product, Cortrophin Gel, which saw sales reach $81.6 million, representing 66% year-over-year and 54% sequential growth. This operational strength led management to raise its full-year 2025 guidance for revenue, adjusted EBITDA, and EPS, with the specific forecast for Cortrophin Gel sales increasing to a range of $322 million to $329 million. The market has responded positively, with the stock gaining 24.8% year-to-date and H.C. Wainwright increasing its price target to $93.00 from $84.00. While fundamental metrics appear healthy, with a current ratio of 2.66 and last-twelve-months revenue growth of 30.3%, a note of caution is warranted as the stock is trading near its 52-week high and is indicated by InvestingPro analysis to be trading above its fair value.

Key Decisions for Investors

• Given the significant earnings beat and raised full-year guidance driven by Cortrophin Gel's momentum, investors may view the operational outperformance as a strong bullish signal for the company's near-term growth trajectory.
• Caution is advised regarding valuation, as the stock is trading near its 52-week high and has been flagged as potentially overvalued, suggesting that new positions should be considered carefully against the risk of a price correction.
• Investors should closely monitor the continued sales performance of Cortrophin Gel and the market adoption of its pre-filled syringe, as these are the critical drivers underpinning the company's enhanced guidance and fundamental outlook.